S. Supiot - Concepedia

Author

S. Supiot

Institut de Cancérologie de l'Ouest ORCID

Also Known As

S SUPIOT, S Supiot, S. Supiot, STEPHANE SUPIOT, SUPIOT, Stéphane, Stephane Supiot, Stéphane Supiot, Stéphane SUPIOT, Stéphane Supiot, Supiot, S.

452

Publications

7.1K

Citations

H-Index

Concepts

All Affiliations

Institut de Cancérologie de l'Ouest Inserm Nantes Université Centre Léon Bérard Institut Bergonié

About

S. Supiot is an author at Institut de Cancérologie de l'Ouest specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	52	3.9K
2	Health Sciences	16	18	1.2K
3	Engineering	3	3	95
4	Social Sciences	1	1	14
5	Biomedical Engineering	1	1	31

S. Supiot

Publications

5.5K

Citations

H-Index

Page 1

	Year	Citations
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design Karim Fizazi, Stéphanie Foulon, Joan Carles, The Lancet Factorial DesignUrology× 2Genitourinary CancerDeprivation Therapy	2022	716
Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer Charles Catton, Himu Lukka, Chu‐Shu Gu, Journal of Clinical Oncology Radiation MedicineNuclear MedicineUrologyRadiation TherapyHypofractionated Radiation Regimen	2017	683
Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial C. Carrié, Ali Hasbini, Guy de Laroche, The Lancet Oncology UrologySurgical OncologySalvage RadiotherapyRadiation TherapyMedicine	2016	356
Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial Paul Sargos, Sylvie Chabaud, I. Latorzeff, The Lancet Oncology Surgical OncologyUrologyRadiation TherapyGenitourinary CancerMedicine	2020	307
Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial C. Carrié, Nicolas Magné, Patricia Burban-Provost, The Lancet Oncology Surgical OncologyUrologyRadiation TherapyGenitourinary CancerMedicine	2019	239
Daily Versus Weekly Prostate Cancer Image Guided Radiation Therapy: Phase 3 Multicenter Randomized Trial R. de Crevoisier, Mohamed Amine Bayar, P. Pommier, International Journal of Radiation OncologyBiologyPhysics Adaptive RadiotherapyRadiation TherapyMedical ImagingMedicineBrachytherapy	2018	119
Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity Ananya Choudhury, Helen Zhao, Farid Jalali, Molecular Cancer Therapeutics	2009	108
A Monoclonal Antibody to O-Acetyl-GD2 Ganglioside and Not to GD2 Shows Potent Anti-Tumor Activity without Peripheral Nervous System Cross-Reactivity Nidia Alvarez-Rueda, Ariane Desselle, Denis Cochonneau, PLoS ONE	2011	93
Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensus Thomas Zilli, Vérane Achard, Alan Dal Pra, Radiotherapy and Oncology	2022	87
Comparison of Automated Atlas-Based Segmentation Software for Postoperative Prostate Cancer Radiotherapy G. Delpon, Alexandre Escande, Timothée Ruef, Frontiers in Oncology	2016	86

Page 1